Capsida Biotherapeutics is a fully integrated next-generation gene therapy platform company that originated from groundbreaking research at Caltech. The company focuses on capsid engineering, cargo optimization, translational biology, process development and manufacturing, and clinical development, with the goal of creating customized therapies for both rare and common diseases across all ages.

Capsida Biotherapeutics

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences Corp.

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Metric
Company Name	Capsida Biotherapeutics	Alkermes plc	Anavex Life Sciences Corp.	Therini Bio
Symbol		ALKS	AVXL
MSH ID	COM:CAPSIDA	COM:ALKERMES	COM:ANAVEX	COM:THERINIBIO
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country		IE	US	US
Stage
Employee Count	51	2.10K	40
Website	capsida.com	alkermes.com	anavex.com	therinibio.com
LinkedIn				therinibio
Founders

Metric
Market Cap		3.89B	391.04M
Enterprise Value
Monthly Web Traffic	4.49K
Web Traffic Growth	0.18
Valuation
Raised Capital

Metric
Revenue		1.66B
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.37B
EBITDA		486.73M
Operating Income		414.12M
Net Income		355.76M
EPS		2.14
Diluted EPS		2.10
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.87
Operating Profit Margin		0.22
EBITDA Margin		0.29
Net Profit Margin		0.25
Return on Equity		0.34
Return on Assets		0.20
Return on Capital Employed		0.23

CAPS

COM:CAPSIDA

Capsida Biotherapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		20.48
P/B Ratio		3.24
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.17
EV Multiple		16.57

Metric
Days Sales Outstanding		78.13
Days Payables Outstanding		94.07
Days Inventory Outstanding		352.33
Operating Cycle		441.02
Cash Conversion Cycle		441.02
Asset Turnover		0.81

Metric
Operating Cash Flow		401.35M
Free Cash Flow		353.31M
Cash Flow to Debt		1.50
Operating Cash Flow/Sales		0.29
Free Cash Flow Yield		0.06

Metric
Cash & Equivalents		457.47M
Accounts Receivable		-44.51M
Inventory		186.41M
Goodwill		83.03M
Debt to Capitalization		0.22
Debt to Assets		0.13
Current Ratio		3.12
Quick Ratio		2.77

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.06
R&D to Revenue		0.19
SG&A to Revenue		0.17